Lingotto Investment Management LLP Has $7.98 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lingotto Investment Management LLP lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 61.4% during the fourth quarter, Holdings Channel reports. The fund owned 89,232 shares of the medical equipment provider’s stock after buying an additional 33,958 shares during the quarter. Lingotto Investment Management LLP’s holdings in Lantheus were worth $7,983,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LNTH. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the period. State of New Jersey Common Pension Fund D increased its position in Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after buying an additional 115 shares in the last quarter. Bleakley Financial Group LLC raised its stake in Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after buying an additional 129 shares during the period. UMB Bank n.a. boosted its holdings in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Lantheus in the third quarter valued at approximately $25,000. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

Shares of LNTH stock opened at $80.07 on Wednesday. The firm has a 50-day moving average of $89.77 and a 200-day moving average of $96.81. Lantheus Holdings, Inc. has a one year low of $56.44 and a one year high of $126.89. The company has a market cap of $5.57 billion, a P/E ratio of 13.32 and a beta of 0.44.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.